JNJ

Johnson & Johnson

182.12
USD
-0.09%
182.12
USD
-0.09%
155.72 186.69
52 weeks
52 weeks

Mkt Cap 479.43B

Shares Out 2.63B

Chat
Send me real-time posts from this site at my email

J&J, BARDA program gives a spot to Australian antiviral nasal spray developer ENA Respiratory

Australia-based ENA Respiratory was selected to join the Blue Knight program set up by Johnson & Johnson (NYSE:JNJ) and Biomedical Advanced Research and Development Authority (BARDA), to help accelerate the development of the company's pan-antiviral nasal spray. ENA said that its self-administered nasal spray INNA-051 has shown pan-antiviral potential with efficacy against a variety of respiratory viruses, including SARS-CoV-2, influenza, and the common cold rhinovirus in pre-clinical research. The company added that it began a phase 2a influenza challenge pre-exposure prophylaxis (preventive) study of INNA-051. The therapy was found to be well-tolerated in a phase 1 trial. ENA had secured a Series A investment from the Brandon Capital Partners' managed funds, the Minderoo Foundation and Uniseed. BARDA operates under U.S. Department of Health and Human Services.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue